Deferiprone in Alzheimer Disease: A Randomized Clinical Trial.

ABSTRACT:

Importance

Interventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide. Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target.

Objective

To investigate whether the brain-permeable iron chelator deferiprone slows cognitive decline in people with AD.

Design, setting, and participants

This phase 2, double-masked, placebo-controlled randomized clinical trial of 12-month duration was conducted at 9 sites in Australia between August 2, 2018, and April 1, 2023. Patients older than 54 years with amyloid-confirmed mild cognitive impairment or early AD (a Mini-Mental State Examination score of 20 or higher) were screened. R

SUBMITTER: Ayton S 

PROVIDER: S-EPMC11536302 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature